The effects of Chinese proprietary medicine and vaccination on patients with COVID-19: a retrospective study in Macao

Abstract Background COVID-19 is continuing to ravage globally and has resulted in a huge health and financial burden. Chinese proprietary medicines, such as Lianhua Qingwen (LHQW) and Huoxiang Zhengqi (HXZQ) capsules, have been recommended for non-high-risk patients with COVID-19 in China. Based on...

Full description

Bibliographic Details

Published in:	Chinese Medicine
Main Authors:	Hui Mo, Man-Fei Zhou, Edmundo Patricio Lopes Lao, Ka-Kei Chan, On-Na Lai, Man-In Ho, Kin-Wa Wong, Ka-Meng Ho, Kin-Tim Sio, Keng-Lam Fong, Yong-Hua Zhao, Seng-Ip Cheang, Iek-Long Lo
Format:	Article
Language:	English
Published:	BMC 2024-01-01
Subjects:	COVID-19 Chinese proprietary medicine Lianhua Qingwen capsule Huoxiang Zhengqi capsule
Online Access:	https://doi.org/10.1186/s13020-023-00877-8